Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5665742 | 0.87 | ALDH1A1 (0.50) | ALDH1A1TSHRTDP1 | |
| SCHEMBL5487582 | 0.81 | ALDH1A1 (0.61) | ALDH1A1TSHRTDP1 | |
| Ether SCHEMBL8068700 | 0.79 | ALDH1A1 (0.33) | ALDH1A1 | |
| Ether SCHEMBL8827195 | 0.79 | TSHR (0.57) | ALDH1A1TSHRTDP1 | |
| Ether SCHEMBL9798268 | 0.76 | ALDH1A1 (0.41) | ALDH1A1TSHR | |
| Ether SCHEMBL10688828 | 0.76 | ALDH1A1 (0.41) | ALDH1A1TSHR | |
| Ether SCHEMBL4973856 | 0.76 | — | — | |
| Ether SCHEMBL10681067 | 0.76 | ALDH1A1 (0.41) | ALDH1A1TSHR | |
| Ether SCHEMBL735420 | 0.76 | — | — | |
| SCHEMBL7155207 | 0.76 | ALDH1A1 (0.53) | ALDH1A1TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 414 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023246854-A1 | CRYSTAL OF BORATE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF | 瑞石生物医药有限公司 | 2023-12-28 | — | — | WO | claimed |
| CN-115368215-A | Synthesis method of bisphenol A hapten | 深圳容金科技有限公司 | 2022-11-22 | — | — | CN | claimed |
| CN-108602914-B | Method for producing highly reactive isobutene homo-or copolymers | 巴斯夫欧洲公司 | 2021-09-24 | — | — | CN | claimed |
| EP-3453703-B1 | CRYSTALLINE FORM E OF TAFAMIDIS MEGLUMINE, PROCESS FOR PREPARATION AND USE THEREOF | CRYSTAL PHARMATECH CO LTD (CN) | 2020-06-24 | — | — | EP | claimed |
| EP-3339306-B1 | CRYSTAL FORM OF 3-(6-(1-(2,2-DIFLUOROBENZO[D][1,3]DIOXOLE-5-YL)CYCLOPROPANE FORMAMIDO)-3-METHYLPYRIDINE-2-YL)BENZOIC ACID AND PREPARATION METHOD THEREOF | CRYSTAL PHARMATECH CO LTD (CN) | 2020-05-06 | — | — | EP | claimed |
| EP-3416992-B1 | PROCESS FOR PREPARING HIGH-REACTIVITY ISOBUTENE HOMO- OR COPOLYMERS | BASF SE (DE) | 2020-04-15 | — | — | EP | claimed |
| EP-3416992-A1 | PROCESS FOR PREPARING HIGH-REACTIVITY ISOBUTENE HOMO- OR COPOLYMERS | BASF SE (DE) | 2018-12-26 | — | — | EP | claimed |
| WO-2017140603-A1 | PROCESS FOR PREPARING HIGH-REACTIVITY ISOBUTENE HOMO- OR COPOLYMERS | BASF SE (DE) | 2017-08-24 | — | — | WO | claimed |
| US-8563530-B2 | Purine nucleoside phosphoramidate | Gilead Pharmassel LLC (US) | 2013-10-22 | — | — | US | claimed |
| EP-2552933-A1 | PURINE NUCLEOSIDE PHOSPHORAMIDATE | Gilead Pharmasset LLC (US) | 2013-02-06 | — | — | EP | claimed |
| US-20110257121-A1 | PURINE NUCLEOSIDE PHOSPHORAMIDATE | PHARMASSET, INC. (US) | 2011-10-20 | — | — | US | claimed |
| WO-2011123672-A1 | PURINE NUCLEOSIDE PHOSPHORAMIDATE | PHARMASSET, INC. (US) | 2011-10-06 | — | — | WO | claimed |
| EP-1590343-B1 | SYNTHESIS OF 2-BUTYL-3-(2' -(1-TRITYL-1H-TETRAZOL-5-YL)BIPHEN YL-4-YL)-1,3-DIAZASPIRO-4,4 -NONENE-4-ONE | TEVA PHARMA (IL) | 2008-07-16 | — | — | EP | claimed |
| EP-1412287-B1 | CATALYST AND ITS USE IN THE SYNTHESIS OF HYDROGEN PEROXIDE | ENI SPA (IT) | 2005-12-28 | — | — | EP | claimed |
| EP-0948584-B1 | FUEL COMPOSITION | BP OIL INT (GB) | 2001-09-12 | — | — | EP | claimed |
| EP-0609089-B1 | Unleaded aviation gasoline | ETHYL PETROLEUM ADDITIVES INC (US) | 1996-11-13 | — | — | EP | claimed |
| US-5426196-A | Synthesis of diaryl methanes | GLAXO INC. (US) | 1995-06-20 | — | — | US | claimed |
| EP-0597520-A1 | Non-pyrophoric lithiumalkyl compounds in powder form and process for their preparation | METALLGESELLSCHAFT AG (DE) | 1994-05-18 | — | — | EP | claimed |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | ABBVIE INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-4118425-A | ISOMERIZATION, DEHYDROGENATION OF ALKANES, ETHERIFICATION | TEXACO INC. (US) | 1978-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257121-A1 | PURINE NUCLEOSIDE PHOSPHORAMIDATE | PNP, NUDT1, TYMP | ALDH1A1 762/4885TSHR 3561/4885TDP1 141/4885 |
| US-20240228509-A1 | MACROCYCLIC MCL-1 INHIBITORS AND METHODS OF USE | MCL1, BCL2A1, BCL2L10 | ALDH1A1 641/4885TSHR 1846/4885TDP1 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.